Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionMolecular phenotyping of a UK population: defining the human serum metabolomeClinical Metabolomics: The New Metabolic Window for Inborn Errors of Metabolism Investigations in the Post-Genomic EraSystems Pharmacology in Small Molecular Drug DiscoveryFitting Transporter Activities to Cellular Drug Concentrations and Fluxes: Why the Bumblebee Can FlyA Dormant Microbial Component in the Development of PreeclampsiaApplying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the futureMetMaxStruct: A Tversky-Similarity-Based Strategy for Analysing the (Sub)Structural Similarities of Drugs and Endogenous MetabolitesRecon 2.2: from reconstruction to model of human metabolismSystems Biology of the FluxomeA Bacterial Component to Alzheimer’s-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to DiseaseBrain Metabolic Changes in Rats following Acoustic TraumaA data preprocessing strategy for metabolomics to reduce the mask effect in data analysis.An analysis of a 'community-driven' reconstruction of the human metabolic networkAnalytical methods in untargeted metabolomics: state of the art in 2015.Systems biology of host-microbe metabolomics.Transparency in metabolic network reconstruction enables scalable biological discoveryGlobal Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of EthambutolEnhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.High-Resolution Metabolomics: Review of the Field and Implications for Nursing Science and the Study of Preterm BirthGlobal metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii.Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels.Synthetic biology for the directed evolution of protein biocatalysts: navigating sequence space intelligently.Lipid and Metabolic Changes in Rheumatoid Arthritis.In silico ADME/T modelling for rational drug design.Advances in metabolome information retrieval: turning chemistry into biology. Part II: biological information recovery.Comparative metabolism of tramadol and tapentadol: a toxicological perspective.Towards quantitative mass spectrometry-based metabolomics in microbial and mammalian systems.Commentary on "Rapid identification of Streptococcus and Enterococcus species using diffuse reflectance-absorbance Fourier transform infrared spectroscopy and artificial neural networks".Is systems pharmacology ready to impact upon therapy development? A study on the cholesterol biosynthesis pathway.The apparent permeabilities of Caco-2 cells to marketed drugs: magnitude, and independence from both biophysical properties and endogenite similarities.Understanding the foundations of the structural similarities between marketed drugs and endogenous human metabolitesWorking Up a Good Sweat - The Challenges of Standardising Sweat Collection for Metabolomics Analysis.A 'rule of 0.5' for the metabolite-likeness of approved pharmaceutical drugs.Analysis of drug-endogenous human metabolite similarities in terms of their maximum common substructures.Mass Spectrometry in Untargeted LC-MS Metabolomics: ESI parameters and global coverage of the metabolome.In silico ADME-Tox modeling: progress and prospects.Metabolomics-Coupled Functional Pharmacology of Chlorophyll Compounds Isolated From the Leaves of Ficus Exasperata Vahl (Moraceae) Provides Novel Pathways on Myometrial Activity.The role of stochastic gene switching in determining the pharmacodynamics of certain drugs: basic mechanisms.8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells.
P2860
Q24273350-E350615C-57B6-4DE3-A432-51D8733703A3Q24289470-F8165F7C-91E6-4DD8-8C4B-56122F62DB23Q26742050-70323892-87C2-40C6-BC9D-ACF2A3F83FF3Q26768459-C66C7195-CD7E-438F-8939-C30988723B9FQ26780025-0E268D83-7C8A-402D-924C-B1F66B0BBB76Q28069689-BF8BF582-777C-4647-9C5F-22CDA8E97672Q28074451-9F7D86F5-0A53-4A05-B85F-E284F2366811Q28597594-A03D1AAD-7CEC-44F8-9EA9-4ED186013D44Q28601559-C3E989D0-77A3-4D54-A8EC-90E523654392Q29040976-98191675-C101-473A-B86B-8A967743FC46Q29248210-42A2ADDC-9D52-4182-AC9F-6B2074480AF0Q30359211-D63C5297-B8D0-4F5B-AE23-C1F2F6CA4512Q30953959-67EB2803-618C-4EF3-80C0-2A2CBA14BF80Q34867072-6555618F-FA78-4EFF-B19F-100777F110D4Q35149924-1C18CDF5-9F8F-4DF0-85BD-87897FF29A9DQ35619563-FA0AC26C-5CFE-4711-BB32-BDBBB15B2F77Q35812551-78B6E021-9762-44B2-A604-DFA001E4D364Q35911355-F2CFEF22-7681-4491-ADDD-3059CF34BFCCQ36342657-3D6497A5-730C-466D-9672-4E3757679C59Q36387102-9A063D21-6217-4A56-BCAE-C4DAB09BD69EQ36628128-333FB9A4-3D1F-4869-A1B3-D63E7F09EEFFQ37668704-617F8262-AD2C-422B-B7E7-976E11DACCB0Q38287400-54AEDE18-9872-4AFD-AD9D-76B24E7CCCC1Q38554197-9F2F24DB-5B22-43F4-9631-B8DF06BB2A5CQ38578341-6D544B62-6474-48A6-9629-A00A1C683A1DQ38607534-9C63294C-8321-484C-BFF4-85B87D0F580CQ38942405-D744E694-FAF1-45C5-BEB3-BA86755EB881Q38958767-796332AE-9D6E-414F-9010-9CE493EC83B0Q38994528-19A7DBCE-5971-4E21-BAAC-A4564352ED98Q40046136-7B7A19C4-980D-4831-90F8-152D52716F68Q40262879-C2BEDF37-A548-469F-94DB-1BF46CF1E737Q40605856-1013AC26-A79F-4708-9B55-9A34A0758702Q41303216-4BC6AFA7-010C-4D6E-AE8D-826137721A0FQ41861993-2299E776-F90D-4183-A095-ECDC2FB58B9AQ41959283-3DAC44A4-F056-435C-8352-466A81961A51Q46563408-EFD6D3E0-441A-40C5-A61D-5D2144E52506Q47658021-82798D9B-7199-4E89-8779-00D081EE22B6Q47917846-8FBBDE52-EE3E-4012-81AA-2158A2FF2756Q48183263-AB33F357-A856-4DFA-854D-6E685EA9E311Q49170560-C357A0DF-2146-42A7-9828-E9372A9378D4
P2860
Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Metabolomics and systems pharm ...... lic network for drug discovery
@ast
Metabolomics and systems pharm ...... lic network for drug discovery
@en
Metabolomics and systems pharm ...... lic network for drug discovery
@nl
type
label
Metabolomics and systems pharm ...... lic network for drug discovery
@ast
Metabolomics and systems pharm ...... lic network for drug discovery
@en
Metabolomics and systems pharm ...... lic network for drug discovery
@nl
prefLabel
Metabolomics and systems pharm ...... lic network for drug discovery
@ast
Metabolomics and systems pharm ...... lic network for drug discovery
@en
Metabolomics and systems pharm ...... lic network for drug discovery
@nl
P2860
P921
P3181
P1433
P1476
Metabolomics and systems pharm ...... lic network for drug discovery
@en
P2860
P304
P3181
P356
10.1016/J.DRUDIS.2013.07.014
P407
P577
2014-02-01T00:00:00Z